LONDON—Proteome Sciences PLC, a global leader in appliedproteomics and peptidomics, has entered into a collaboration agreement with therenowned Moffitt Cancer Center to develop mass spectrometry assays measuringcertain key signaling and repair pathway proteins that can be adapted for tumorbiopsy analysis in the clinic.
According to Proteome Sciences, the technical collaborationwill enable the extension of Moffitt's activities to incorporate a large numberof key proteins and post-translational modifications to rapidly translatelaboratory tests into the direct management of cancer patients.
"We believe that knowledge of the molecular switchesoperating within each individual tumor will allow better selection andmonitoring of treatment efficacy," said Dr. John Koomen, principal investigatorat the cancer center, in a statement.
These new methods, capable of simultaneously measuring thesechanges across several pathways, are urgently needed to deliver better outcomesin all cancers, stated Dr. Ian Pike, chief operating officer of ProteomeSciences.
"We identified the expertise of the Koomen lab as beinghighly complementary to our own focus of profiling post-translationalmodifications in major human disease," he added. "We are delighted to beworking with John and look forward to launching a number of new MS assaysarising from this collaboration."
Located in Tampa, Fla., the Moffitt Cancer Center is aNational Institutes of Health Comprehensive Cancer Center. The center has 14affiliates in Florida, one in
Georgia, one in Pennsylvania and two in Puerto Rico.Additionally, Moffitt is a member of the National Comprehensive Cancer Network,a prestigious alliance of the country's leading cancer centers, and is listedin U.S. News & World Report as oneof "America's Best Hospitals" for cancer.
